Apalutamide: First Global Approval

Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines

(2018) Michael I. Koukourakis et al.   ANTI-CANCER DRUGS

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

(2018) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective

(2018) Madeline Cancian et al.   UROLOGY

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

(2016) Matthew R. Smith et al.   EUROPEAN UROLOGY

Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management

(2016) Francois Rozet et al.   WORLD JOURNAL OF UROLOGY

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

(2013) Dana E. Rathkopf et al.   JOURNAL OF CLINICAL ONCOLOGY

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH